TruSight Oncology 500 and TruSight Oncology 500 High Throughput: Introduction & Overview

TruSight Oncology 500 is a next-generation sequencing tumor profiling assay that analyzes 523 genes for cancer-related biomarkers with FFPE samples. The assay supports the identification of DNA and RNA variants implicated in various tumor types, including measuring key immunotherapy biomarkers such as tumor mutation burden (TMB) and microsatellite instability (MSI). This webinar focuses on introducing TruSight Oncology 500/TruSight Oncology 500 High Throughput library preparation and is targeted at new users of the workflow. We cover the following topics: how to successfully prepare and sequence TruSight Oncology 500 libraries, comparison of TruSight Oncology 500 and TruSight Oncology 500 High Throughput workflows, and how to assess key sequencing metrics

View upcoming Support Webinars
https://support.illumina.com/training...

Subscribe to the Illumina video channel http://www.youtube.com/subscription_c...

A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.

*Data calculations on file. Illumina, Inc., 2015.

View customer spotlight videos
   • Illumina Customer Testimonials  

View Illumina webinars
   • Webinars  

View Illumina product videos
   • Плейлист  

View Illumina support videos
   • Illumina Support